MDNA Life Sciences, Inc., is pioneering the development of molecular tests based on the mitochondrial genome in order to improve clinical insight and therapeutic decisions that affect patients worldwide. The unique structural and functional characteristics of mitochondrial DNA (mtDNA) make it a highly attractive system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting.

The Company’s revenue-generating Prostate Core Mitomic Test™ (PCMT™) is the highest performing tissue-based prostate cancer diagnostic on the market with a significantly greater tumor field effect that allows 85% sensitivity and 92% negative predictive value. Leveraging its unparalleled insights into the role of mtDNA, the company is developing an extensive and proprietary portfolio of blood-based molecular tests addressing significant unmet needs in prostate and other cancers, as well as other high-need disease states including endometriosis. MDNA launched its first blood-based test for prostate cancer in 2016 and plans to launch its blood-based test for endometriosis in 2017.